Bayer and Atara Biotherapeutics (ATRA) Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. ACN
3. IBM
4. MU
5. DPZ
6. NVDA
7. PRIM
8. META
9. SPY
10. SPCX

Go back to Bayer and Atara Biotherapeutics (ATRA) Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

ATARA Biotherapeutics (ATRA) Prices 5.102M Share Common Offering at $24.50/Sh

December 9, 2020 6:11 AM EST

Atara Biotherapeutics, Inc. (NASDAQ: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,102,041 shares of its common stock at a price to the public of $24.50 per share and, to... More